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to γ‑aminobutyric acid‑A, γ‑aminobutyric acid‑B and 
glycine receptors: immunopathogenic mechanisms 
and clinical characteristics
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Recent, discoveries of neural antibodies have facilitated the diagnosis of immune‑mediated, immunotherapy‑responsive neurologic 
disorders. Antibodies that target inhibitory central nervous system receptors, such as γ‑aminobutyric acid‑B, γ‑aminobutyric 
acid‑A, and glycine receptors, disrupt inhibitory regulatory synaptic functions, and lead to neuronal hyperexcitability. The myriad 
of neurologic, manifestations associated with these antibodies includes seizures, encephalopathy, muscle rigidity and stiffness. 
This article provides a review of the immunopathogenic mechanisms and the clinical and therapeutic implications of autoimmune 
encephalitis associated with these antibodies that target inhibitory receptors.
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INTRODUCTION
Recent, discoveries of neural antibodies that bind to 
antigenic targets in the brain have led to a paradigm 
shift in the clinical approach to patients presenting with 
encephalopathy,[1‑4] cognitive change,[5] and refractory 
seizures.[4,6] With a wider availability of neural antibody 
testing, a significant proportion of the patients, who were 
previously diagnosed with encephalitis of undetermined 
etiology have been shown to have neurologic symptoms 
caused by an underlying autoimmune disorder and some 
of these patients respond favorably to immunosuppressive 
treatments.[7] Neural antibodies that, target channels or 
receptors on the neuronal cell surface can interfere with 
the function of these proteins, leading to altered neuronal 
excitability, and a myriad of neurologic syndromes that 
mirror genetic and pharmacologically induced disorders 
of the target receptors.[8] In this review, we describe 
the immunopathogenic mechanisms of autoimmune 
encephalitis associated with antibodies targeting the 
inhibitory synaptic receptors γ‑aminobutyric acid‑B 
(GABAB), γ‑aminobutyric acid‑A (GABAA), and glycine 
receptors (GlyRs), together with their clinical and 
therapeutic implications.
ANTI‑GABAB RECEPTOR AND ANTI‑GABAA 
RECEPTOR ENCEPHALITIS
GABA, the main inhibitory neurotransmitter in the brain, 
binds to metabotropic and ionotropic receptors to regulate 
neuronal activity. To date, GABAB receptor (GABABR) 
and GABAA receptor (GABAAR) have been identified as 
antigenic targets of autoimmunity [Table 1].
Anti‑GABA
B
R encephalitis
The GABABR is a metabotropic G‑protein‑coupled 
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receptor on presynaptic, postsynaptic, and extrasynaptic 
membranes, expressed in both the central and peripheral 
nervous systems, particularly the hippocampus, thalamus, 
and cerebellum.[9] This receptor is a heterodimer comprising 
two subunits: GABAB1 and GABAB2. Both subunits need to 
be co‑expressed in order to form a functional receptor.[9,10] 
The extracellular domain of the GABAB1 subunit binds 
to GABA while the GABAB2 subunit couples the receptor 
with the effector G protein.[11] Antibodies to GABABR 
bind to the B1 subunit of the GABABR,
[4] the component 
that is required for GABA binding and receptor function.
GABABR exert inhibitory regulatory effects on synaptic 
transmission by inhibiting presynaptic voltage‑gated 
calcium channel‑mediated neurotransmitter release 
and by activating postsynaptic potassium channels, 
resulting in hyperpolarization of neuronal membranes, 
and inhibition of adenylate cyclase.[11,12] GABABR 
dysfunction is implicated in a variety of neurological 
disorders such as epilepsy, in which genetic mutations 
may play a role.[13,14] Pharmacological disruption of 
the GABABR leads to seizures, cognitive deficits, and 
behavioral changes,[10,15,16] all of which may be seen in 
autoimmune anti‑GABABR limbic encephalitis.
Antibodies to GABABR were first described in 15 
patients with limbic encephalitis, in whom subacute 
early onset of seizures was a distinctive feature.[4] 
Seizures were predominantly of temporal lobe onset 
with secondary generalization, and 3 of the 15 patients 
developed status epilepticus. Memory impairment, 
confusion, hallucinations, and behavioral changes 
consistent with limbic involvement were frequently 
seen. Electroencephalography (EEG) changes included 
epileptiform discharges, electrographic ictal activity, 
and/or temporal lobe slowing.
Magnetic resonance imaging (MRI) brain imaging 
typically demonstrates unilateral or bilateral increased 
T2/fluid attenuated inversion recovery signal changes 
in the medial temporal region, consistent with limbic 
encephalitis.[4,17] Extratemporal changes in the grey and 
white matter, cerebellum, basal ganglia, and brainstem 
have also been reported.[4,17‑19] Cerebrospinal fluid 
(CSF) examination may yield lymphocytic pleocytosis, 
elevated protein, and oligoclonal bands.[4] As with other 
types of limbic encephalitis, the EEG, MRI brain, and/or 
CSF exam may be normal, and should not preclude the 
diagnosis or presumptive treatment when the clinical 
presentation is suspicious. 
Limbic encephalitis, the most common neurologic 
manifestation of anti‑GABABR encephalitis,
[4,20,21] 
typically occurs in the setting of very high GABABR 
antibody titers.[4,20] A widening phenotypic spectrum of 
anti‑GABABR disorders including cerebellar ataxia,
[17,20,22,23] 
opsoclonus‑myoclonus,[17,18] and brainstem encephalitis[19] 
is now appreciated. Extralimbic presentations may be 
explained by the high expression of GABABR outside 
of the hippocampus, including the cerebellum.[9] Other 
rarer neurological features of anti‑GABABR encephalitis 
include chorea, myelopathy, peripheral neuropathy, and 
myopathy, particularly in patients with lower antibody 
titers.[4,20] It is uncertain, whether all of these extralimbic 
neurologic manifestations can be attributed solely to the 
GABABR antibodies or whether the co‑existence of other 
neural autoantibodies may contribute to the increasingly 
diverse neurological features being reported. Known 
neural antibody accompaniments to the GABABR 
antibodies include the 65 kDa isoform of glutamate 
decarboxylase (GAD‑65), voltage‑gated calcium channels 
(N‑type and P/Q type), voltage‑gated potassium‑complex 
(VGKC‑complex), and neuronal nuclear and cytoplasmic 
antibodies [such as antineuronal nuclear autoantibody 
(ANNA‑1), ANNA‑3, collapsing response mediator 
protein‑5 IgG, and anti‑glial nuclear autoantibody/SOX‑1 
antibodies].[4,20‑22]
In comparison to other cell surface neural antibody 
associated encephalitis, anti‑GABABR encephalitis 
is probably uncommon. In a clinical service 
laboratory,  only 7 of 3,989 (0.2%) patients with 
suspected  autoimmune encephalopathy were found 
to have the GABABR antibody.
[20] There is no obvious 
gender predisposition for this neurologic disorder. A 
paraneoplastic etiology is diagnosed in approximately 
half of the patients with GABABR antibodies.
[4,17,20,21] 
The neurologic disorder usually precedes the diagnosis 
of malignancy, and the most frequently encountered 
tumor is small cell lung cancer.[4,20] Tumors are more 
likely to be detected in older patients.[4] Although, lung 
tumors from patients with GABABR encephalitis have 
not been studied for GABABR expression, samples of 
archived small cell lung cancers from patients without 
encephalitis were found to react with both guinea pig 
and human GABAB IgG. This suggests that the GABABR 
could be expressed by small cell lung cancer and could 
potentially trigger an autoimmune reaction.[4] Other 
oncologic associations of anti‑GABABR encephalitis 
include neuroendocrine lung tumor, multiple myeloma, 
esophageal carcinoma, malignant melanoma, and 
carcinoid of the thymus.[4,19,20,22,23]
Neurological improvement has been reported in up 
to 90% of patients with anti‑GABABR encephalitis 
who received immunotherapy and appropriate cancer 
treatment (if the tumor was detected).[4,17,20,21] As the 
cases reported so far were retrospectively ascertained, 
there was heterogeneity in the immunotherapies used. A 
variety of immunotherapie have been used successfully, 
including various combinations of first‑line agents, 
corticosteroids, intravenous immunoglobulin (IVIg), 
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and/or plasma exchange (PLEX).[4,20] Patients who 
do not respond to these treatments warrant second 
line and maintenance treatments, such as rituximab, 
cyclophosphamide, mycophenolate mofetil, and 
azathioprine.[17,20,23,24] Neurological improvement may 
be incomplete or not sustained. Despite optimal 
immunosuppressive treatment, patients with GABABR 
antibodies can deteriorate due to tumor progression, 
chemotherapy‑related complications, and/or 
treatment‑resistant relapses.[4,17,22‑24] Further studies to 
elucidate the optimal treatment regimens are needed. 
The presence of an underlying small cell lung cancer 
and the co‑existence of other paraneoplastic neural 
antibodies targeting intracellular (neuronal nuclear 
and cytoplasmic) antigens have been suggested as poor 
prognostic indicators.[17,20]
Anti‑GABAAR encephalitis
The GABAAR is a ligand‑gated ion channel located at 
synaptic and extrasynaptic sites that functions to mediate 
fast inhibitory synaptic transmission.[25,26] Activation 
of the GABAAR triggers opening of intrinsic chloride 
channels, thereby eliciting an inhibitory postsynaptic 
potential.[27] Disruption of GABAAR results in increased 
neuronal excitability and seizures.[27] Mutations in the 
α1 and β3 subunits of the GABAAR gene have been 
implicated in epilepsy syndromes.[27‑29] Benzodiazepine 
and barbiturate, medications used for the treatment of 
seizures and status epilepticus, enhance GABAergic 
inhibition to exert an anticonvulsant effect.[30]
GABAARs are pentamers comprising combinations 
of five subunits that form chloride ion channels. 
Different combinations of subunits result in functional 
heterogeneity. Synaptic GABAARs, which contain the 
α (α1‑3), β, and γ subunits, are responsible for phasic 
inhibition. By contrast, extrasynaptic and perisynaptic 
GABAARs, which are responsible for tonic inhibition, 
comprise α4 or α6 subunits combined with β and δ 
subunits.[31] The GABAAR antibody binds to the α1,β3, 
or both subunits of the synaptic GABAAR.
[32,33] GABAAR 
antibodies reduce the density of the GABAAR at synaptic 
sites when applied to rat hippocampal neurons, suggesting 
that antibody binding leads to the relocation of GABAAR 
from the synaptic membrane.[32,33] This phenomenon is 
similar to the loss of synaptic GABAAR and resultant 
neuronal hyperexcitability observed in epilepsy and 
status epilepticus.[27] The combined reinforcing effects 
of antibody‑mediated synaptic GABAAR relocation, 
together with the status epilepticus‑induced loss of 
GABAAR, could support a postulated model to explain 
the severity of seizures in patients with anti‑GABAAR 
encephalitis.[33]
Recently, 18 patients with autoimmune encephalitis 
and prominent seizures were described with GABAAR 
antibodies, 6 of  whom had very high antibody 
titers.[33] Patients with high titers in both serum and 
CSF developed a particularly rapid, severe progressive 
encephalopathy with refractory seizures and/or status 
epilepticus, for which intensive care admission for 
pharmacologically‑induced coma was required. Other 
reported clinicalmanifestations in GABAAR antibody 
seropositive patients are opsoclonus‑myoclonus, affective 
problems, hallucinations, mutism, aphasia, memory 
impairment, hemiparesis, chorea, cerebellar ataxia, 
and Stiff‑man syndrome (SMS).[32,33] GABABR, GAD‑65, 
N‑methyl‑D‑aspartate receptor (NMDAR), leucine‑rich, 
glioma‑inactivated 1 and contactin‑associated protein‑like 
2 antibodies frequently co‑exist in these patients.[32,33] A 
propensity for other neurological autoimmune conditions 
such as myasthenia gravis has also been noted.[32,33]
GABAAR antibodies are reported in both children 
and adults (age 2‑74 years), but larger cohorts need 
to be characterized.[33] A low frequency of tumors in 
seropositive patients has been reported. In the initially 
published study of 18 patients, only one patient was 
found to have cancer (Hodgkin lymphoma).[33]Two recent 
additionally reported cases had invasive thymoma.[32]
The electroencephalograms of patients with 
anti‑GABAAR encephalitis may demonstrate generalized 
slowing suggestive of encephalopathy, multifocal 
ictal and interictal discharges, or status epilepticus.[33] 
CSF findings range from normal to lymphocytic 
pleocytosis.[33] Distinctive to GABAAR antibodies, the 
majority of patients, especially those with high antibody 
titers, had extensive temporal and extratemporal MRI 
brain abnormalities[33] which could be a consequence of 
autoimmune inflammation in the brain or prolonged ictal 
activity. The extensive radiologic changes contrast with 
those of patients with limbic encephalitis  associated 
with other neuronal synaptic and cell surface antibodies, 
such as NMDAR and VGKC‑complex antibodies, in 
which MRI abnormalities are often confined to the 
mesial temporal regions.
Despite the severity of their presentation, 80% of the 
patients reported with anti‑GABAAR encephalitis 
demonstrate partial or complete recovery with a 
combination of  immunotherapy, antiepileptic drugs, 
and supportive treatment.[32,33] In severe cases, multiple 
immunotherapies may be required. Treatment options 
are the same as with GABABR and GlyR antibody 
mediated disorders. In addition to immunotherapy, 
early recognition and treatment of epilepsy, as well as 
supportive treatment (including ventilation support) are 
pivotal.
GlyR antibody encephalitis
Glycine, a key neurotransmitter for fast postsynaptic 
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inhibitory neurons in the CNS, has a complex functional 
pathway that involves pre‑ and post‑synaptic GlyR 
interacting with other neurotransmitters (GABA and 
glutamate), NMDAR, and postsynaptic anchoring 
proteins like gephyrin. Antibodies directed at any 
of these targets may affect the glycinergic system, 
resulting in neurological dysfunction.[34] Whether due 
to strychnine (a GlyR antagonist) poisoning, genetic 
mutations of the GlyR gene (hereditary hyperekplexia), 
or immune‑mediated encephalitis, GlyR dysfunction 
may be associated with severe muscle spasms, stiffness, 
agitation, seizures, myoclonus, autonomic instability, 
and/or respiratory failure.[35,36]
GlyRs, pentamers of α1‑α4 and β‑subunit proteins, are 
ligand‑gated chloride ion channels,  widely distributed 
in the CNS. They are predominantly expressed in 
the olfactory bulb, retina, hippocampus, brainstem 
(auditory, visual, vestibular, and sensory nuclei), 
cerebellum, and spinal cord.[37,38] Glycine binding 
mediates opening of the GlyR chloride channel, resulting 
in hyperpolarization of the membrane potential and 
reduced neuronal excitability. The GlyR antibody targets 
the α1 subunit of the postsynaptic GlyR and is associated 
with hyperexcitable neurologic disorders [Table 1].[39] 
Gephyrin allows multiple GlyR to cluster together on 
the synaptic membrane. Antibodies to gephyrin, an 
anchoring protein in the postsynaptic GlyR, have been 
described only in a single case to date.[40]
Classic neurologic manifestations associated with GlyR 
antibodies are progressive encephalomyelitis with 
rigidity and myoclonus (PERM) and SMS.[39,41,42] PERM 
and SMS were first described as separate clinical entities, 
but today these 2 conditions are considered to belong 
to a continuum of CNS hyperexcitability disorders. 
Patients with PERM and SMS share common features 
of rigidity, painful spasms, autonomic disturbances, 
hyperekplexia, and myoclonus. The widespread 
distribution of hyperexcitability and brainstem 
involvement classically distinguishes PERM from SMS 
and associated psychiatric symptoms such as anxiety 
are more commonly observed in SMS patients.[43‑46] 
The autoimmune nature of these conditions, and 
specifically the involvement of GlyR antibodies in 
some cases was not appreciated until recently.[41,42] 
SMS was initially associated with antibodies to 
GAD‑65 (60‑70% of cases),[47,48] gephyrin (1 case),[40] and 
amphyiphysin (< 5% cases, in the setting of both small 
cell lung and breast cancers).[48,49] In 2008, Hutchinson 
et al.[41] reported the first case of PERM with GlyR 
antibodies. It remains unresolved whether all of these 
Table 1: Key demographic, clinical, and AI/oncologic associations of the GABABR, GABAAR, and GlyR-α1 antibodies
GABABR GABAAR GlyR-α1
Clinical features Limbic encephalitis (memory 
impairment, hallucination, 
confusion, behavior changes) with 
early and prominent seizuresLess 
commonly: cerebellar ataxia, 
opsoclonus‑myoclonus, brainstem 
encephalitis, chorea, myelopathy, 
peripheral neuropathy, and myopathy
High serum antibodies concentration: 
rapidly progressive encephalopathy, 
refractory seizures, and status 
epilepticusLow serum antibodies 
concentration: seizures, SMS, 
opsoclonus‑myoclonus, behavioral 
change, psychosis, confusion, chorea, 
ataxia, hallucinations, and hemiparesis
Axial/limb spasms, rigidity, and myoclonus 
(SMS) + brainstem signs (PERM) 
Optic neuropathy, seizures, cognitive 
impairment, autonomic disturbance, 
respiratory failure, and transverse 
myelitis also reported in isolation or with 
SMS or PERM
Onset Mostly subacute/acute Acute/subacute Subacute > acute > chronic
Age group Wide range, children, and adults Wide range, children, and adults Wide range, children, and adults
Gender, male:female 1.3:1 2:1 1:1
Inflammatory CSF*  73% 40% 50%, but OCB frequently negative
MRI 65% abnormal (medial temporal > 
extratemporal changes)
High serum antibodies concentration: 
100% multifocal temporal 
and extratemporal T2/FLAIR 
hyperintensities
< 30% T2/FLAIR abnormalities in 
temporal lobes, SC abnormalities rarely 
reported (short, multifocal, and LETM)
EMG ‑ ‑ 60% abnormal (continuous motor activity, 
stimulus induced motor activity)
Other coexisting 
neural antibodies
56% (VGCC, AGNA, GAD‑65, 
VGKC‑complex, NMDAR, ANNA‑1, 
‑2 and ‑3,CRMP‑5 IgG, amphiphysin, 
BRSK2)
70% (AChR, NMDAR, GABAB, GAD‑65, 
VGKC‑complex)
Rare (GAD‑65, MOG, NMDAR, 
aquaporin‑4, VGKC‑complex)
Associated tumors  62% (SCLC most common, also 
neuroendocrine lung, malignant 
melanoma, esophageal, malignant 
melanoma, thymus anaplastic carcinoid)
15% (invasive thymoma, Hodgkin 
lymphoma)
Approximately 10% to date (breast 
cancer, lymphoma (both Hodgkin and 
NHL), leukemia, lung cancer, melanoma)
Fatalities (%) 36 20 < 10
*Inflammatory CSF includes pleocytosis, high protein, raised IgG index, and/or oligoclonal bands. AChR: acetylcholine receptor; AI: autoimmune; AGNA: anti‑glial 
nuclear autoantibody; ANNA: antineuronal nuclear autoantibody; BRSK2: BR serine/threonine‑protein kinase‑2; CRMP‑5: collapsing response mediator protein 5; CSF: 
cerebrospinal fluid; EEG: electroencephalogram; EMG: electromyography; FLAIR: fluid attenuated inversion recovery; GABAAR: γ‑aminobutyric acid receptor A subunit; 
GABABR: γ‑aminobutyric acid receptor B subunit; GAD‑65: glutamic acid decarboxylase‑65; GlyR‑α1: glycine receptor alpha‑1 subunit; LETM: longitudinally extensive 
transverse myelitis; MOG: myelin oligodendrocyte glycoprotein; MRI: magnetic resonance imaging; NHL: nonHodgkin lymphoma; NMDAR: N‑methyl‑D‑aspartate receptor; 
OCB: oligoclonal bands; PERM: progressive encephalomyelitis with rigidity and myoclonus; SC: spinal cord; SMS: stiff‑man syndrome; SCLC: small cell lung carcinoma; 
VGCC: voltage‑gated calcium channel; VGKC‑complex: voltage‑gated potassium channel complex
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antibodies are truly pathogenic.[50,51] McKeon et al.[42] 
reported that 10 of 81 (12%) patients with SMS 
spectrum disorders were positive for GlyR antibodies. 
Interestingly, GlyR seropositivity was associated with 
better responsiveness to immunotherapy regardless of 
GAD‑65 status, suggesting a pathogenic role. There are 
no passive transfer animal models of GlyR antibodies to 
date.[39,42]
The spectrum of GlyR antibody encephalitis 
manifestations is now widening beyond classic 
PERM and SMS. Various combinations of psychiatric 
disturbances, cognitive dysfunction, seizures (focal/
generalized epilepsy and new‑onset status epilepticus), 
and movement disorders, autonomic instability 
with central hypoventilation, pseudobulbar and/or 
oculomotor dysfunction, steroid responsive optic 
neuropathy, and transverse myelopathy have now been 
described with GlyR antibodies.[39,52‑54]
The onset of symptoms in GlyR antibody neurologic 
syndromes is typically acute to subacute. In the largest case 
series of 52 GlyR antibody positive patients with a variety 
of presentations, there appears to be no sex predominance 
and all age groups are vulnerable.[39] Patients frequently 
have a history of other autoimmune disorders.[39] As with 
other autoimmune encephalopathies, GlyR antibodies 
may co‑exist with other antibodies, such as NMDAR, 
GAD‑65, VGKC‑complex, myelin oligodendrocyte 
glycoprotein, and aquaporin‑4 antibodies although this 
is rare.[39,42,53,55,56] Tumors are identified in less than 20% 
of cases (thymoma, lymphoma, breast cancer, small cell 
lung carcinoma and leukemia).[39,42,57,58]
GlyR antibodies may be detected in both serum and/or 
the CSF.[39,59] CSF evaluation is possibly more sensitive 
than serum, therefore testing both is recommended.[42] 
CSF lymphocytic pleocytosis or raised protein may be 
seen, and oligoclonal bands were negative in 50‑70% of 
2 case series recently published.[39,56] Imaging is typically 
normal. Rarely, MRI temporal lobe T2‑weighted 
abnormality with subsequent hippocampal volume 
loss is detected, particularly in cases associated with 
significant seizure activity. EEG may be normal, or show 
features of focal or generalized ictal activity.[59]
A combination of immunotherapies (corticosteroids, 
IVIg, PLEX, cyclophosphamide), pharmacological 
therapies targeting symptoms of motor hyperexcitability 
and pain (clonazepam, diazepam, baclofen, gabapentin), 
and anticonvulsants (levetiracetam) are  required to 
control clinical symptoms.[39,42] Eighty percent of patients 
with GlyR antibodies showed a substantial response 
to immunotherapy.[39,42] Two cases were reported that 
responded dramatically to thymectomy in addition 
to other immunotherapy.[39,60] In the largest case series 
to date, 6 out of 52 (12%) patients continued to have 
sporadic relapses whilst on treatment.[39]
CONCLUSION
An increased awareness of the autoimmune mechanisms 
underlying cases of noninfective encephalitis and/or 
refractory seizures has led to increased recognition, 
earlier treatment, and improved outcomes in a subgroup 
of patients previously considered untreatable. Antibodies 
targeting the inhibitory receptors GABAB, GABAA, 
and glycine are three more recently appreciated, but 
important antibodies to consider in refractory seizure 
disorders and encephalitis of unclear etiology. A high 
index of suspicion and an awareness of the expanding 
clinical spectrum of these antibody‑mediated disorders 
should prompt early neural antibody testing in patients 
with typical constellations of neurological symptoms, in 
particular refractory seizure disorders and encephalitis 
of unclear etiology. Once identified early, these 
conditions may be responsive to immunotherapy. There 
are sparse data to recommend one immunotherapeutic 
regime over another. Large cohort studies of patients 
with anti‑NMDAR encephalitis  suggest that first line 
therapy should comprise corticosteroids, IVIg, and/
or PLEX, followed by second line immunotherapy 
(cyclophosphamide, rituximab, or both) in patients 
who fail to respond to initial treatment.[61] A practical 
approach, guided by the literature on autoimmune 
encephalitis with antibodies against neuronal surface 
antigens, is suggested in Figure 1. Immunotherapy 
needs to be complemented by supportive, symptomatic 
medical therapy. There is a consensus that early 
treatment confers better outcomes. Age and antibody 
appropriate tumor screening should be performed in all 
cases and may be aided by testing for other co‑existing 
neural antibodies.[62]
The neurologic hyperexcitability effects of antibody 
binding to GABAA, GABAB, and GlyRs (and potentially 
other receptors in the future) reflect the important 
functions mediated by these inhibitory neuronal synaptic 
receptors. More research is needed in order to better 
understand this novel category of immune‑mediated 
encephalitis. Further studies could focus on 
immunopathogenic mechanisms of these antibodies 
in causing disease, as these may be potential targets 
for directed treatment. To date, the numbers of patients 
reported with these antibodies remain small, with most 
cases retrospectively identified. With increasing access 
to testing for neural antibodies, the clinical spectrum 
of these autoimmune encephalitides may continue to 
expand. Systematic studies of prospectively identified, 
newly diagnosed cases should help to provide data on 
the long‑term course of the disease, prognostic factors, 
and optimal immunotherapeutic regimes.
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